Importance of cyclosporine pharmacokinetics to clinical outcomes after liver transplantation

Transplantation Proceedings

Volumn 30, Issue 5, 1998, Pages 1826-1827

  Levy, G A ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A;

CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; GRAFT REJECTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEPHROTOXICITY; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; CANADA; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; LIVER TRANSPLANTATION; METABOLIC CLEARANCE RATE;

EID: 0031716287     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0041-1345(98)00446-1     Document Type: Conference Paper

References (4)

1. Freeman D, Grant D, Levy GA: Ther Drug Monit 17:213, 1995
2. Lindholm A, Henricsson S, Lind M, et al: Eur J Clin Pharmacol 34:461, 1988
3. Vonderscher J, Meinzer A: Transplant Proc 26:2925, 1994
4. Levy G, Altraif I, Rezieg M, et al: Transplant Proc 26:3184, 1994